Technical Analysis for CUE - Cue Biopharma, Inc.

Grade Last Price % Change Price Change
grade D 6.76 -1.60% -0.11
CUE closed down 1.6 percent on Monday, October 15, 2018, on 57 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Down Down
See historical CUE trend table...

Date Alert Name Type % Chg
Oct 15 New 52 Week Closing Low Bearish 0.00%
Oct 15 Calm After Storm Range Contraction 0.00%
Oct 15 Inside Day Range Contraction 0.00%
Oct 15 Wide Bands Range Expansion 0.00%
Oct 15 Down 3 Days in a Row Weakness 0.00%
Oct 15 Oversold Stochastic Weakness 0.00%
Oct 12 New 52 Week Closing Low Bearish -1.60%
Oct 12 New Downtrend Bearish -1.60%
Oct 12 Lower Bollinger Band Walk Weakness -1.60%
Oct 12 New 52 Week Low Weakness -1.60%

Older signals for CUE ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
Basic chart:
Profile
  • Earnings date: 2018-11-12
Cue Biopharma Inc is a biopharmaceutical company developing a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders.
Is CUE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Oct 10 The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares
Oct 9 The Daily Biotech Pulse: Affimed's Cancer Drug Placed On Clinical Hold, Celgene's Positive Scalp Psoriasis Trial
Sep 28 Premarket analyst action - healthcare
Aug 27 Cue Biopharma, Inc. (CUE) CEO Dan Passeri Hosts Investor Business Update Call (Transcript)
Aug 24 Cue Biopharma (CUE) Investor And Analyst Update - Slideshow
Aug 3 Cue Biopharma Adds Frank Morich, M.D., Ph.D. to Board of Directors
Aug 3 The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings
Aug 1 Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial
Jul 24 Cue Biopharma Appoints Bethany Mancilla as Chief Business Officer and Senior Vice President
Jul 12 Cue Biopharma Produces Immuno-STAT™ Biologic Candidate for Treatment of Autoimmune Disease Under Collaboration and License Agreement with Merck
See more CUE news...
Indicators
Indicator Value
52 Week High 17.99
52 Week Low 6.4
Average Volume 94,155
200-Day Moving Average 0.0
50-Day Moving Average 8.5672
20-Day Moving Average 8.28
10-Day Moving Average 7.498
Average True Range 0.6228
ADX 26.31
+DI 14.1835
-DI 29.2375
Chandelier Exit (Long, 3 ATRs ) 7.8316
Chandelier Exit (Short, 3 ATRs ) 8.2684
Upper Bollinger Band 10.0352
Lower Bollinger Band 6.5248
Percent B (%b) 0.07
BandWidth 42.396135
MACD Line -0.5752
MACD Signal Line -0.4078
MACD Histogram -0.1674
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.65
Resistance 3 (R3) 7.70 7.45 7.50
Resistance 2 (R2) 7.45 7.23 7.43 7.45
Resistance 1 (R1) 7.11 7.09 6.99 7.06 7.40
Pivot Point 6.86 6.86 6.80 6.84 6.86
Support 1 (S1) 6.52 6.64 6.40 6.47 6.12
Support 2 (S2) 6.27 6.50 6.25 6.07
Support 3 (S3) 5.93 6.27 6.02
Support 4 (S4) 5.88